Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Heier JS, et al. Among authors: figueroa ms. Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085502 Clinical Trial.
Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme.
Holz FG, Bandello F, Gillies M, Mitchell P, Osborne A, Sheidow T, Souied E, Figueroa MS; LUMINOUS Steering Committee. Holz FG, et al. Among authors: figueroa ms. Br J Ophthalmol. 2013 Sep;97(9):1161-7. doi: 10.1136/bjophthalmol-2013-303232. Epub 2013 Jul 13. Br J Ophthalmol. 2013. PMID: 23850682 Free PMC article.
A delphi study to detect deficiencies and propose actions in real life treatment of neovascular age-related macular degeneration.
García-Layana A, Arias L, Figueroa MS, Araiz J, Ruiz-Moreno JM, García-Arumí J, Gómez-Ulla F, López-Gálvez MI, Cabrera-López F, García-Campos JM, Monés J, Cervera E, Armadá F, Gallego-Pinazo R, Piñero-Bustamante A, Serrano-Garcia MA. García-Layana A, et al. Among authors: figueroa ms. J Ophthalmol. 2014;2014:595132. doi: 10.1155/2014/595132. Epub 2014 Dec 21. J Ophthalmol. 2014. PMID: 25587438 Free PMC article.
Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept.
García-Layana A, Figueroa MS, Araiz J, Ruiz-Moreno JM, Gómez-Ulla F, Arias-Barquet L, Reiter N. García-Layana A, et al. Among authors: figueroa ms. Drugs Aging. 2015 Oct;32(10):797-807. doi: 10.1007/s40266-015-0300-y. Drugs Aging. 2015. PMID: 26442858 Free PMC article. Review.
Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration.
García-Layana A, Figueroa MS, Arias L, Araiz J, Ruiz-Moreno JM, García-Arumí J, Gómez-Ulla F, López-Gálvez MI, Cabrera-López F, García-Campos JM, Monés J, Cervera E, Armadá F, Gallego-Pinazo R. García-Layana A, et al. Among authors: figueroa ms. J Ophthalmol. 2015;2015:412903. doi: 10.1155/2015/412903. Epub 2015 Sep 27. J Ophthalmol. 2015. PMID: 26491550 Free PMC article. Review.
100 results